Non-Invasive Biomarkers of NASH

Non-Invasive Biomarkers of NASH

The following publication discusses the latest research regarding the Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis (NASH).  Nature Medicine originally published this article, coauthored by ERG’s Vice President of Clinical Pharmacology Services Clay Dehn, on February 10th, 2022. This browser does not support PDFs. Please download the PDF to view it: Download PDF.

STUDIES ARE ENROLLING NOW!

Nonalcoholic Fatty Liver Disease (NAFLD)

NAFLD is the most common form of chronic liver disease in the US. Find out if you’re at risk today by taking part in a clinical trial enrolling now. 

Knee Pain

Apply to participate in a study of an investigational pain medication following a knee replacement.

Smoking Study

Are you a current smoker? You may qualify for a clinical trial evaluating various heated tobacco products.